On Monday, for the second time in as many business days, Illumina (ILMN -5.47%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% lower, during a session when the S&P 500 (^GSPC 0.67%) landed in the black with a 0.7% increase.The move is to sell now, says bankThat morning, Barclays changed its recommendation on Illumina stock to underweight (read: sell) from the previous equal weight (hold). It also pulled the lever on a significant price ...

Have you assessed how the international operations of Illumina (ILMN) performed in the quarter ended December 2024? For this genetic testing tools company, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth journey. Investors mu ...

Illumina (NASDAQ: ILMN ) reached a solid profitability level thanks to Grail divestment and a cost-cutting plan. Free Cash Flow is increasing and could reach $1.2bn for the FY25, yielding more than 6% on the enterprise value. However, bad newsHello readers! Passionate about technology, my focus will be on finding and analyzing companies that can play a relevant role in today's geopolitics, leverage their IP, and eventually, with time, become new leaders. Therefore, the investment style will correspond to gr ...

Shares of Illumina (ILMN -8.47%) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m. ET. At that time, the S&P 500 had slid by 0.9% and the Nasdaq Composite was down 1.4%.Illumina, a biotech company that develops and manufactures genetic testing systems, reported disappointing fourth-quarter numbers after the closing bell Thursday.The numbersIllumina's revenue has stagnated or declined for several years now, and its total s ...

Illumina, Inc. ILMN reported better-than-expected results for its fourth quarter on Thursday.The company posted quarterly earnings of 95 cents per share which beat the analyst consensus estimate of 92 cents per share. The company reported quarterly sales of $1.10 billion which beat the analyst consensus estimate of $1.08 billion.“The Illumina team delivered fourth quarter revenue that exceeded our expectations, and we made significant progress in 2024 toward our goals to drive customer-centric innovation, m ...

Illumina Inc. (ILMN) reported fourth-quarter 2024 adjusted earnings per share (EPS) of 86 cents, which missed the Zacks Consensus Estimate of 92 cents by 6.5%. The bottom line was significantly above the year-ago quarter’s level of 14 cents. Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The adjustments exclude the impact of GRAIL’s pre-acquisition net operating losses on GILTI, the utilization of U.S. foreign tax credits and the Pillar Two global minimum top-up tax, which became eff ...

Financial Data and Key Metrics Changes - In Q4 2024, Illumina reported revenue of $1.1 billion, reflecting approximately 1% growth year-over-year, driven primarily by consumables [15][34] - Non-GAAP gross margins for Q4 were 67.4%, an increase of 270 basis points year-over-year, attributed to operational excellence initiatives and growth in consumables [37] - Non-GAAP EPS for Q4 was $0.95, exceeding expectations due to higher revenue and a lower tax rate [39] Business Line Data and Key Metrics Changes - Sequencing consumables revenue was $698 million, growing approximately 2% year-over-year, driven by the transition to NovaSeq X [35] - Sequencing instruments revenue declined 3% year-over-year to $155 million, primarily due to a decrease in mid-throughput shipments [36] - Total sequencing GB output grew over 30% year-over-year, indicating robust growth from both clinical and research customers [36] Market Data and Key Metrics Changes - Revenue from the Americas, which constitutes more than half of Illumina's business, increased by 3% year-over-year [17] - EMEA revenue decreased by 10%, while Greater China revenue increased by 1% [17] Company Strategy and Development Direction - Illumina aims to return to revenue growth in 2025 and achieve high single-digit growth by 2027, focusing on customer collaboration, continuous innovation, and operational excellence [13][18] - The company is transitioning to the NovaSeq X series, with expectations that over 75% of high-throughput gigabases will be shipped on this platform by mid-2025 [44] - Illumina is enhancing partnerships, such as with NVIDIA, to leverage AI tools for better data analysis and interpretation [19][144] Management's Comments on Operating Environment and Future Outlook - Management is closely monitoring the evolving political and macroeconomic environment, particularly regarding research funding and the recent announcements from China [27][42] - For 2025, Illumina expects low single-digit revenue growth and a non-GAAP operating margin of approximately 23%, reflecting a 170 basis points improvement from 2024 [28][46] - The company remains committed to supporting global customers and advancing scientific discovery through genomics [28] Other Important Information - Illumina achieved over $100 million in cost savings in 2024 through improved manufacturing and logistics efficiencies [26] - The company ended Q4 with approximately $1.22 billion in cash and short-term investments, indicating a strong cash generation profile [41] Q&A Session Summary Question: Update on China revenue mix and guidance implications - Management acknowledged that China represents about 7% of total revenue and is assessing the situation, but did not provide detailed financials [57][58] Question: Insights on Q1 revenue cadence - Management indicated that top-line growth is expected to be stronger in the second half of the year, driven by the NovaSeq X transition [60] Question: Volume growth and pricing dynamics - Management noted that volume growth is expected to remain strong, with mid-20% growth anticipated in the longer term [69] Question: Clarification on clinical transition and gigabyte shipments - Management stated that approximately 50% of clinical volume has transitioned to the NovaSeq X series, with expectations for further growth [77] Question: Margin protection strategies amid China uncertainties - Management is exploring all opportunities for margin expansion and operational leverage, aiming for 170 basis points of margin improvement year-over-year [91] Question: R&D investment strategy - Management confirmed that R&D spending will remain below $1 billion per year, focusing on optimizing costs and driving innovation [149]

For the quarter ended December 2024, Illumina (ILMN) reported revenue of $1.1 billion, down 1.6% over the same period last year. EPS came in at $0.86, compared to $0.14 in the year-ago quarter.The reported revenue represents a surprise of +2.64% over the Zacks Consensus Estimate of $1.08 billion. With the consensus EPS estimate being $0.92, the EPS surprise was -6.52%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expec ...

Illumina (ILMN) came out with quarterly earnings of $0.86 per share, missing the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6.52%. A quarter ago, it was expected that this genetic testing tools company would post earnings of $0.87 per share when it actually produced earnings of $1.14, delivering a surprise of 31.03%.Over the last four quarter ...

Revenue Performance - Q4 2024 revenue of approximately $1.10 billion, up 1% from Q4 2023[4] - Full-year 2024 revenue of approximately $4.33 billion, down 2% from 2023[4] - Fiscal year 2025 guidance: constant currency revenue growth in the low single digits, with reported revenue expected between $4.28 billion and $4.4 billion[4] Operating Margin - GAAP operating margin of 16.7% for Q4 2024 and 34.2% for full-year 2024[4] - Non-GAAP operating margin of 19.7% for Q4 2024 and 21.3% for full-year 2024[4] - Non-GAAP operating margin expected to be approximately 23% for fiscal year 2025[4] Earnings Per Share (EPS) - GAAP diluted EPS of $0.77 - $0.79 for Q4 2024 and $5.65 - $5.67 for full-year 2024[4] - Non-GAAP diluted EPS of $0.91 - $0.93 for Q4 2024 and $4.12 - $4.14 for full-year 2024[4] - Non-GAAP diluted EPS growth expected to be approximately 10% for fiscal year 2025[4] Cash Flow - Free cash flow of approximately $1.07 billion for 2024[4]